| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $0 | 0 | 0 |
Sells | $13,052,875 | 45 | 100 |
| Inrig Jula | CHIEF MEDICAL OFFICER | 0 | $0 | 6 | $226,162 | $-226,162 |
| ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | 0 | $0 | 4 | $414,149 | $-414,149 |
| Baynes Roy D. | director | 0 | $0 | 2 | $540,000 | $-540,000 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER | 0 | $0 | 7 | $584,042 | $-584,042 |
| Coughlin Timothy | director | 0 | $0 | 1 | $630,601 | $-630,601 |
| REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | 0 | $0 | 5 | $766,281 | $-766,281 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | 0 | $0 | 8 | $877,977 | $-877,977 |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | 0 | $0 | 6 | $3.47M | $-3.47M |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | 0 | $0 | 6 | $5.54M | $-5.54M |
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Travere Therapeutics, Inc. have bought $0 and sold $13.05M worth of Travere Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Travere Therapeutics, Inc. have bought $0 and sold $5.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $178,500 was made by ASELAGE STEVE (Chief Executive Officer) on 2017‑06‑14.
| 2025-12-15 | Sale | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | 2,910 0.0034% | $36.00 | $104,760 | -0.42% | |
| 2025-12-01 | Sale | Cline Christopher R. | CHIEF FINANCIAL OFFICER | 20,000 0.0222% | $35.01 | $700,202 | -0.84% | |
| 2025-11-04 | Sale | Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | 67,115 0.0768% | $36.00 | $2.42M | +1.99% | |
| 2025-10-31 | Sale | Heerma Peter | CHIEF COMMERCIAL OFFICER | 5,591 0.0064% | $35.00 | $195,685 | -1.22% | |
| 2025-10-31 | Sale | Coughlin Timothy | director | 18,000 0.0206% | $35.03 | $630,601 | -1.22% | |
| 2025-10-29 | Sale | Dube Eric M | CHIEF EXECUTIVE OFFICER | 27,128 0.0326% | $30.12 | $817,074 | +15.84% | |
| 2025-10-28 | Sale | Dube Eric M | CHIEF EXECUTIVE OFFICER | 92,872 0.1124% | $30.38 | $2.82M | +16.50% | |
| 2025-10-28 | Sale | Heerma Peter | CHIEF COMMERCIAL OFFICER | 2,662 0.0032% | $30.00 | $79,860 | +16.50% | |
| 2025-09-22 | Sale | REED ELIZABETH E | Chief Legal Officer and GC | 10,000 0.011% | $25.00 | $250,000 | +31.77% | |
| 2025-09-04 | Sale | Cline Christopher R. | CHIEF FINANCIAL OFFICER | 119 0.0001% | $19.71 | $2,345 | +36.64% | |
| 2025-09-03 | Sale | Cline Christopher R. | CHIEF FINANCIAL OFFICER | 454 0.0005% | $18.20 | $8,263 | +43.55% | |
| 2025-08-27 | Sale | Cline Christopher R. | CHIEF FINANCIAL OFFICER | 470 0.0005% | $17.31 | $8,136 | +59.92% | |
| 2025-07-01 | Sale | Inrig Jula | CHIEF MEDICAL OFFICER | 815 0.0009% | $14.65 | $11,940 | +67.30% | |
| 2025-05-05 | Sale | Dube Eric M | CHIEF EXECUTIVE OFFICER | 18,924 0.021% | $21.05 | $398,350 | -5.02% | |
| 2025-05-05 | Sale | Heerma Peter | CHIEF COMMERCIAL OFFICER | 1,771 0.002% | $21.05 | $37,280 | -5.02% | |
| 2025-05-05 | Sale | ROTE WILLIAM E. | Chief Research Officer | 3,198 0.0035% | $21.05 | $67,318 | -5.02% | |
| 2025-05-05 | Sale | Cline Christopher R. | CHIEF FINANCIAL OFFICER | 1,784 0.002% | $21.05 | $37,553 | -5.02% | |
| 2025-05-05 | Sale | REED ELIZABETH E | Chief Legal Officer and GC | 4,920 0.0054% | $21.05 | $103,566 | -5.02% | |
| 2025-04-11 | Sale | Cline Christopher R. | CHIEF FINANCIAL OFFICER | 48 <0.0001% | $13.14 | $631 | +37.59% | |
| 2025-02-12 | Sale | Heerma Peter | CHIEF COMMERCIAL OFFICER | 2,568 0.0029% | $23.53 | $60,426 | -14.57% |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | 419173 0.4685% | $15.03M | 0 | 30 | |
| Heerma Peter | CHIEF COMMERCIAL OFFICER | 119071 0.1331% | $4.27M | 0 | 24 | |
| ROTE WILLIAM E. | Chief Research Officer | 100241 0.112% | $3.59M | 0 | 42 | |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | 92083 0.1029% | $3.3M | 0 | 18 | |
| REED ELIZABETH E | Chief Legal Officer and GC | 89878 0.1005% | $3.22M | 0 | 43 | |
| Inrig Jula | CHIEF MEDICAL OFFICER | 88787 0.0992% | $3.18M | 0 | 13 | |
| Coughlin Timothy | director | 55500 0.062% | $1.99M | 0 | 1 | |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | 45635 0.051% | $1.64M | 0 | 19 | |
| Baynes Roy D. | director | 31000 0.0347% | $1.11M | 0 | 2 | |
| Shkreli Martin | 1765168 1.973% | $63.28M | 39 | 8 | +21.5% | |
| Shih Alvin | EVP of Research & Development | 158334 0.177% | $5.68M | 0 | 6 | |
| ASELAGE STEVE | 146919 0.1642% | $5.27M | 4 | 37 | +123.45% | |
| Richardson Steven Gary | director | 129165 0.1444% | $4.63M | 3 | 0 | +123.82% |
| PANOFF MARC L | Chief Financial Officer | 121100 0.1354% | $4.34M | 1 | 0 | +138.48% |
| Plotkin Horacio | Chief Medical Officer | 91767 0.1026% | $3.29M | 1 | 2 | +138.48% |
| Meckler Jeffrey A | director | 81000 0.0905% | $2.9M | 3 | 1 | +66.46% |
| Paley Jeffrey | director | 51665 0.0577% | $1.85M | 0 | 1 | |
| LYONS GARY A | director | 51000 0.057% | $1.83M | 0 | 1 | |
| VALEUR JENSEN MARGARET E | General Counsel | 50000 0.0559% | $1.79M | 0 | 1 | |
| Rosenberg Noah L. | Chief Medical Officer | 47614 0.0532% | $1.71M | 0 | 15 | |
| Clague Laura | Chief Financial Officer | 35655 0.0399% | $1.28M | 0 | 28 | |
| McFarlane Neil F. | Chief Operating Officer | 26988 0.0302% | $967,519.80 | 0 | 5 | |
| Golding Cornelius E | director | 25000 0.0279% | $896,250.00 | 2 | 0 | +115.2% |
$193,151,375 | 134 | 8.18% | $3.36B | |
$11,588,217 | 69 | 42.07% | $2.97B | |
Travere Therapeutics, Inc. (TVTX) | $11,583,737 | 45 | 49.75% | $3.21B |
$224,382,625 | 44 | 27.62% | $3.31B | |
$104,428,685 | 44 | 22.55% | $3.01B | |
$148,770,544 | 34 | 80.63% | $3.09B | |
$5,066,938 | 27 | 26.38% | $3.32B | |
$150,253,463 | 26 | -52.83% | $3.46B | |
$25,045,414 | 23 | -3.79% | $2.96B | |
$174,105,409 | 15 | 10.88% | $3.2B | |
$137,027,226 | 13 | 28.32% | $3.49B | |
$1,248,715 | 10 | 5.66% | $3.42B | |
$45,445,266 | 9 | -24.96% | $2.96B | |
$32,575,266 | 8 | 37.03% | $3.32B | |
$4,623,072 | 7 | 11.07% | $3.31B | |
$91,589,325 | 7 | -6.97% | $2.79B | |
$24,000,085 | 4 | 33.26% | $3.45B | |
$142,493,653 | 3 | 4.30% | $3.03B | |
$7,600,000 | 1 | -4.05% | $2.84B |
| Increased Positions | 129 | +52.87% | 17M | +17.02% |
| Decreased Positions | 107 | -43.85% | 17M | -16.82% |
| New Positions | 55 | New | 5M | New |
| Sold Out Positions | 26 | Sold Out | 3M | Sold Out |
| Total Postitions | 266 | +9.02% | 103M | +0.2% |
| Janus Henderson Group Plc | $369,186.00 | 11.91% | 10.6M | +1M | +11.09% | 2025-09-30 |
| Blackrock, Inc. | $282,139.00 | 9.1% | 8.1M | -68,490 | -0.84% | 2025-09-30 |
| Armistice Capital, Llc | $234,197.00 | 7.56% | 6.72M | -2M | -24.25% | 2025-09-30 |
| Vanguard Group Inc | $230,344.00 | 7.43% | 6.61M | +619,085 | +10.33% | 2025-09-30 |
| Macquarie Group Ltd | $173,604.00 | 5.6% | 4.98M | -113,149 | -2.22% | 2025-09-30 |
| Perceptive Advisors Llc | $132,166.00 | 4.26% | 3.79M | +3M | +354.85% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $123,716.00 | 3.99% | 3.55M | +768,000 | +27.59% | 2025-09-30 |
| State Street Corp | $112,077.00 | 3.62% | 3.22M | -265,337 | -7.62% | 2025-09-30 |
| Fmr Llc | $100,803.00 | 3.25% | 2.89M | +2M | +171.04% | 2025-09-30 |
| Rock Springs Capital Management Lp | $75,399.00 | 2.43% | 2.16M | +256,565 | +13.45% | 2025-09-30 |